From French Labs to Hospitals: The 50-year story of Modafinil

Paris, 1973. 
Inside a quiet lab at the French pharmaceutical company L. Lafon Ltd., two researchers named Gombert and Assous were chasing the opposite of what they would eventually find. Dr Michel Jouvet, a neuroscientist obsessed with sleep, and his team weren’t trying to keep people awake. They were trying to make sleep safer. At the time, the go-to drugs for narcolepsy and extreme fatigue were amphetamines. They worked, but they also came with a cost, such as jitters, crashes and a high risk of dependence. It was like a barter system. Patients had to trade their sleepiness issues with a different kind of problem. 

Lafon’s goal was simple: create a compound that promoted wakefulness without acting like a classic stimulant. So they started synthesising new molecules. One day, they made a batch of benzhydryl sulfinyl compounds. On paper, it looked perfect and promising. The team gave it to lab animals expecting mild sedation. What happened next didn’t make sense. Instead of sleeping, the animals stayed alert, calm, focused and awake-but without the frantic energy that is caused by amphetamines. The fun part is the scientists had created the opposite of a sleeping pill. 

They named it modafinil, after its chemical family. For years, it sat in research files while Lafon figured out what to do with a drug that didn’t fit in any existing category. It wasn’t a stimulant. It wasn’t a sedative. It was something new. By the 1980s, the French Air Force and Air France pilots were quietly testing it for long-haul fatigue. By 1998, the US FDA approved it as Provigil for Narcolepsy. The lab mistake had turned into a mistake. 

Not a Stimulant – A wakefulness switch

For years, reporters identified Modafinil as a “smart drug”. Scientists named it as something else: a eugeroic. Eugeroic comes from a Greek word where “Eu” means ‘good’ and ‘egersis’ means ‘arousal’. When translated into English, it means ‘good wakefulness’. 

In the 1970s, most wakefulness drugs worked like sledgehammers. Amphetamines dumped huge amounts of dopamine and adrenaline into the brain all at once. You felt wired. Then you crashed. Your body paid for it later. Modafinil did something different. Instead of flooding the brain, it seemed to flip a switch. Researchers found it worked mainly in areas of the brain that control the sleep and wake cycle – especially the hypothalamus. That’s the body’s internal clock room. Think of it like this:

• Amphetamines are pouring gasoline on a fire. Bright, fast, messy.
• Modafinil=turning on the lights in a dark room. Steady, targeted. 

It didn’t make people feel high. Patients described it as a normal feeling but staying “awake”. For someone with narcolepsy who could fall asleep mid-conversation, that difference was everything. Even today, 50 years later, scientists are still studying it. What they do know is Modafinil increases signals for wakefulness, like orexin and histamine, while having a much lower effect on the reward circuit that drives addiction. It was approved in many countries but only for specific sleep disorders like Narcolepsy, Sleep apnoea and Shift Work Sleep Disorder. The accidental molecule from Paris hadn’t just kept people awake. It has given physicians a new way to think about being awake. 

Human Side: I Got my Days back

For most of medical history, Narcolepsy was treated like a punchline. 

“Falling asleep in class.” “Can’t stay awake driving.”

But for people living with it, it wasn’t funny. It was losing hours of your life. In the 1980s and 90s, when modafinil started reaching hospitals in France and later in the US, physicians noticed something different in their patients. This wasn’t the wired, anxious energy of old stimulants. 

Patients would come back for follow-ups and say the same thing in different ways:

“I stayed awake through my daughter’s school play.”

“I made it through a full workday without having to pull over.”

“For the first time in years, I feel like me in the mornings.”

That’s because Modafinil wasn’t approved as a focus booster. In the UK, Europe and Germany, regulators only cleared it for 3 specific medical reasons:

• Narcolepsy-sudden sleep attacks
• Obstructive Sleep Apnea-extreme daytime sleepiness even with CPAP treatment
• Shift Work Sleep Disorder-when your body clock and job schedule don’t match

For these patients, Modafinil wasn’t about doing more. It was about doing normal. Going to work. Driving safely. Staying present. By the early 2000s, sleep clinics across Europe had added it to their toolkit. Not as a miracle. As an option. One more tool to give people back the control of their waking hours. The lab accident in Paris in 1973 had finally made it to the people that it was meant for. 

From Medicines to Headlines

By the 2010s, Modafinil had a new problem: it was famous for the wrong reason. A movie came out. Articles started calling it “the smart drug”. University students, startup founders, and night-shift coders started asking physicians about it. Suddenly, a medicine made for Narcolepsy patients was being discussed as a “productivity hack”.  As Modafinil became more widely known, interest extended beyond the medical conditions for which it is prescribed. Researchers have explored its effects in a variety of settings, and discussions about its potential uses have appeared in academic literature and the media. However, these uses are not part of its approved indications.

Healthcare professionals may sometimes prescribe medicines “off-label” when they judge that doing so is appropriate for an individual patient. Off-label prescribing is a clinical decision based on the patient’s circumstances, available evidence and professional judgement. Patients should never start or use medicines for unapproved purposes without consulting a qualified healthcare professional.

The Real Discovery

The story of modafinil isn’t really about a pill that keeps you up. It’s about a French lab in 1973 that set out to make sleep safer. It’s about a mistake that became a new category of medicine. And it’s about patients who for the first time got to choose what they did with their daytime. Michel Jouvet and the Lafon team weren’t looking for “limitless”. They were looking for dignity. For people whose bodies kept shutting down without permission. 

In that, they succeeded. 

50 years later, Modafinil is still a reminder that the biggest discoveries often happen when you’re looking for something else.